Pancreatic cancer patients are frequently characterized with noteworthy mutations in four essential genes, including KRAS. In PDAC patients, the mutational activation of the proto-oncogene KRAS occurs in 85–90% of cases [9,10,11]. Here, KRAS is linked to pancreatic neoplasm.